Parallel Health World News Logo

Parallel Health World

cropper
  • Home
  • Categories
    • EcoHealth Trends
    • Healing Naturally
    • Age-Defying Diets
    • Supplement Savvy
    • Mind-Body Synergy
    • Finance and Health
    • Biolimitless
    • Tech Hacks
    • Health & Medicine
    • Political
    • BioBuzz
    • Holistic Rehabilitation Techniques
    • Practitioner Insights
    • AI In Healthcare
  • Featured Business Profiles
August 15.2026
3 Minutes Read

Neural Therapeutics Receives Conditional CSE Approval: A New Frontier in Health Technology

Professionals discussing documents related to Neural Therapeutics CSE Approval in an office setting

The Emergence of Neural Therapeutics in the Health Sector

In an age where technology meets healthcare, the approval of Neural Therapeutics by the Canadian Securities Exchange (CSE) is a significant step forward. As a promising new company focusing on neural therapies, its conditional approval marks a pivotal moment in the merging domains of biotechnology and financial markets. This advance illuminates the potential for innovative healthcare solutions driven by cutting-edge technology. The company aims to target various neural-related conditions, elevating the discussion around the intersection of technology and health.

Understanding the Impact of This Approval

The conditional approval from the CSE sets the stage for Neural Therapeutics to operate publicly, enabling it to garner investment and expand its research into neural-based treatments. This is particularly vital as the health sector increasingly leans towards integrative practices that leverage technology for better patient outcomes. The potential applications of neural therapeutics span several conditions, from neurological disorders to mental health issues like anxiety and depression, showing promise in offering relief through innovative methods.

This approval opens doors for public awareness and investment, enhancing research funding for advancements in specific treatment protocols. As investors look to support companies that contribute to significant health solutions, Neural Therapeutics positions itself to attract attention, not only for its scientific endeavors but also for its potential market value.

Current Trends Converging at the Intersection of Technology and Health

Recent trends in technology and health underscore the urgency for advancements such as those proposed by Neural Therapeutics. The rise of telemedicine, artificial intelligence, and data analytics reflects a transformative shift towards technology-driven health solutions. Telemedicine offers patients easier access to healthcare professionals, while AI enhances diagnostic accuracy and treatment efficacy, making healthcare more personalized.

These trends reveal a society that increasingly values accessibility and efficiency in healthcare—the foundations upon which Neural Therapeutics seeks to build its services. For instance, using virtual reality as a therapeutic tool for pain management is becoming increasingly common, and Neural Therapeutics' work may intersect with these advancements, enhancing patient engagement and outcomes.

Future Predictions: The Rise of Biotech Companies in Public Markets

With the approval of Neural Therapeutics, we can anticipate a surge in biotech companies tapping into public markets. As investors recognize the potential both for profit and for social impact through innovative health solutions, this sector could witness unprecedented growth. Neural Therapeutics' focus highlights the palpable demand for alternative therapies, particularly as public interest grows towards personalized medicine and holistic health approaches.

Moreover, the approval could inspire confidence in not only established companies but also startups entering the biotech arena. As these companies gain visibility, they may attract new investors who are eager to support the latest innovations in health technology, thereby nurturing a culture of constant advancement and evolution within the industry.

Innovative Funding Opportunities in Health Technology

Reflecting on Neural Therapeutics' achievement reveals wider implications for funding opportunities within the health technology landscape. As more companies receive similar endorsements, the flow of capital into the biotech space may accelerate. Investors looking for unique opportunities will find a rich ground in companies striving for advancements in health solutions driven by technology.

Neural Therapeutics can pave the way for others by showcasing the balance between innovation and public investment. As funding streams increase, we may see a rise in collaborative efforts among various players in the biotech field, such as partnerships between universities and clinical research organizations, which could enhance the pace of discovery and implementation of new therapies.

Conclusion: What This Means for You

The recent approval of Neural Therapeutics not only represents a milestone in health technology but also signifies shifting tides in investment focus. For individuals and practitioners interested in the intersection of technology and health, following developments in companies like Neural Therapeutics can provide insights into future healthcare innovations.

The evolving landscape suggests that by staying informed, you may uncover opportunities to engage with companies driven by advancements in neuro-therapy, influencing both personal health and wider societal benefits. Considering the broader implications of such innovations may lead to more informed decisions for investors, healthcare professionals, and patients alike, promoting a future where technology and health solutions are inextricably linked.

Tech Hacks

1 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
08.13.2026

Unlocking Potential: How LIS Technologies' K-1580 Acquisition Transforms Healthcare and Tech

Update Investing in the Future: LIS Technologies' Acquisition Explained The recent announcement by LIS Technologies Inc. regarding the acquisition of the K-1580 facility for $6.2 million is a pivotal move, not just for the company, but also for the broader industry of nuclear technologies and medical isotopes. Nestled in the historic Heritage Center of Oak Ridge, Tennessee, this 37,800 square-foot building represents a strategic expansion aimed at enhancing the production of key stable isotopes and enriching nuclear fuel. The Silicon Valley of Nuclear: A Historical Context Oak Ridge has long been pivotal in the development of nuclear technology, standing as a cornerstone of the Manhattan Project during World War II. The acquisition of facilities like K-1580 is not just a business decision; it's a continuation of the legacy that has established this region as a leader in nuclear advancements. The K-1580 building complements LIST's existing operations at the adjacent K-1330 building, doubling down on its commitment to innovative nuclear applications, particularly in medical fields. Why Isotopes Matter: Bridging the Gap Between Technology and Healthcare Medical isotopes are essential in diagnostic imaging and cancer treatment. Hospitals rely on these isotopes for PET scans and therapies that can save lives. With K-1580 poised to produce both stable and enriched isotopes, LIST is positioning itself to meet a growing demand. The ability to provide hospitals with a reliable supply can dramatically improve patient outcomes. Additionally, stable isotopes are crucial for fields beyond medicine, including advanced electronics, quantum computing, and even renewable energy. Future Predictions: Opportunities in Medical and Technological Innovations The global market for medical isotopes and stable isotopes is expanding rapidly, and LIST is at the forefront of this trend. Analysts predict that as technological innovations require more sophisticated isotopes, companies like LIST may see exponential growth. Specifically, advancements in quantum technologies and renewable energy systems are likely to depend heavily on stable isotopes for effective operation and reliability. Local vs. Global Perspectives: Implications of the Acquisition This acquisition not only reflects LIST's ambitions but also signals to the global community that the U.S. is serious about staying competitive in the nuclear technology market. While significant research and development occurs internationally, LIST's expansion sends a message that local facilities can meet global needs. Oak Ridge is set to continue being a hub for innovation, and this acquisition strengthens its reputation within both national and international circles. Practical Insights: What This Means for Investors and Stakeholders For investors, understanding the implications of LIST's expansion is crucial. The growth trajectory in the sector is promising, driven by technological advancements and an increasing reliance on medical isotopes. Stakeholders should consider how LIST's new capabilities may generate revenue streams beyond traditional nuclear applications, setting a precedent for other companies in the industry. Conclusion: Embracing Change in the Nuclear Sector As LIS Technologies embarks on this new chapter, the future looks optimistic. The acquisition of K-1580 positions the company effectively to become a key player in the burgeoning fields of medical and stable isotopes, while also tapping into advanced technology sectors. It's a powerful reminder of the interconnectedness of healthcare and technological advancements in today's rapidly changing world.

08.01.2026

WELLSTAR Secures $50 Million Financing: Implications for Healthcare Investors

Update WELLSTAR’s Strategic Financing: Setting the Stage for GrowthWELLSTAR Technologies Corp., a subsidiary of WELL Health Technologies Corp., has secured C$50 million in financing, a significant step as it prepares for its upcoming listing on the TSX Venture Exchange (TSXV). This financing, comprising C$36.2 million from a treasury offering and C$13.8 million from an existing shareholder's secondary offering, is indicative of the confidence that investors have in WELLSTAR’s business model and future prospects. With the backing of a large managed asset firm and additional institutional investors, WELLSTAR is well-positioned to harness cutting-edge technology and innovation within Canada’s healthcare sector.WELL Health: Pioneering the Digital Health LandscapeAs Canada's largest outpatient healthcare company, WELL Health has established itself as a leading provider of technology-driven healthcare solutions. The firm plays a crucial role by operating about 270 clinics that service over five million patients yearly. Notably, WELLSTAR not only focuses on electronic medical records but also integrates AI-powered clinical tools and patient engagement platforms, reflecting a broader trend where technology and healthcare converge. This creates a seamless experience for healthcare practitioners, ultimately enhancing patient care.The Road to TSXV: What it Means for StakeholdersThe planned listing of WELLSTAR's subordinate voting shares on the TSXV signals a strategic move to increase capital for further acquisitions, AI innovations, and growth initiatives. Industry analysts suggest that this listing could provide WELLSTAR with the visibility and financial scale needed to differentiate itself in a competitive landscape. With the closing of the amalgamation and expected trading debut in September, stakeholders, including investors and health practitioners alike, might find new opportunities for engagement within this advancing framework.Future Innovations: Healthcare Meets AIThe infusion of C$50 million will primarily support AI-related initiatives, which stands at the forefront of healthcare innovation. AI technology has the potential to reshape how healthcare services are delivered, from diagnostics to patient management. For example, AI algorithms can analyze vast datasets to identify health patterns, predict outcomes, and personalize patient care. This capability highlights an ongoing trend where technological advancements correlate with improved health outcomes, setting benchmarks for others in the industry.Investor Confidence Amid Market ChallengesThe response from investors echoes a broader market trend favoring healthcare technology companies. Amidst the backdrop of ongoing healthcare challenges globally, the investment enthusiasm demonstrates a belief in sustainable models that prioritize both growth and profitability. WELLSTAR’s management, led by CEO Amir Javidan, underscores that this financing reflects investor confidence, which is essential for navigating markets rife with economic uncertainty.Navigating the Future of Canadian HealthcareWELL Health and WELLSTAR are not merely participants; they are leaders in shaping the future of healthcare technology in Canada. Given the current healthcare environment, characterized by rising demands for digital solutions, WELL Health’s model aligns with the needs of patients and providers alike. As these offerings evolve, the implications for stakeholders, including patients, providers, and investors, could lead to a more integrated and efficient healthcare system.Conclusion: What Lies AheadThe C$50 million financing transaction marks a pivotal moment for WELLSTAR Technologies Corp. Looking ahead to its TSXV listing, stakeholders can anticipate further developments in AI innovation and the growth of digital health solutions. For investors and practitioners interested in the intersection of healthcare and technology, this is an opportunity to engage with a firm positioned to redefine health outcomes in Canada.

07.25.2026

Why Investors Should Watch TelyRx's Q2 2026 Financial Results Call

Update TelyRx: A New Player in Digital Pharmacy Services TelyRx Holdings Inc., based in Clearwater, Florida, operates at the forefront of healthcare innovation with its technology-enabled pharmacy services. The company aims to redefine how patients access prescriptions and medication delivery. Their platform connects patients with licensed providers, offering a wide selection of medications available across the United States. Understanding the Conference Call Announcement The upcoming conference call scheduled for August 10, 2026, at 8:30 AM ET, presents an opportunity for stakeholders and interested parties to learn about TelyRx's financial performance for the second quarter of the year. Such conference calls are especially crucial as they provide insights not just into financial numbers but also into the strategic direction of the company. Why Investors Should Tune In The financial results, expected to be released at 7:00 AM ET on the same day, will highlight key metrics that can influence investor decisions significantly. Given the rapid evolution in the healthcare sector, particularly in digital services, TelyRx's performance may indicate broader market trends that could impact investments in similar companies. Expectations for Quarter Two 2026 For many companies, the second quarter can set the tone for the rest of the fiscal year. Investors will be keen to gauge how TelyRx has fared in terms of revenue growth, customer acquisition, and operational efficiencies. The results will be vital for analysts looking to assess the company’s market positioning amidst ongoing digitization in healthcare. The Digital Pharmacy Landscape The demand for digital pharmacy services has surged in recent years, underscoring the importance of companies like TelyRx. Digital platforms are facilitating quicker access to medications and streamlined prescription processes, proving valuable during crises such as the COVID-19 pandemic. TelyRx stands out with its commitment to seamless delivery systems that connect patients directly to independent pharmacy practitioners. Applying This Knowledge in Healthcare Investments The insights gained from the upcoming conference call may not just reflect TelyRx's individual performance, but they can also serve as a litmus test for the health of the digital pharmacy sector overall. Investors and healthcare analysts alike should consider how TelyRx's operational successes or challenges could mirror experiences in the broader market. Connecting with Stakeholders As healthcare continues to embrace technological integration, stakeholders in the industry should consider maintaining an open line of communication. Conference calls like the one TelyRx is hosting provide a platform for discourse between management, investors, and patients, reinforcing the need for transparency and collaboration in shaping the future of healthcare. What’s Next for TelyRx? The digital pharmacy space is rife with opportunities and challenges. As TelyRx prepares for the conference call, industry insiders will likely scrutinize its strategy for future growth. Continual advancements in technology and shifts in patient expectations will play critical roles in determining how successful TelyRx and similar companies will be. Navigate the evolving landscape of digital health by staying informed. Engaging with TelyRx's upcoming financial results will grant you important insights not only about the company but about the future of healthcare delivery models themselves.

Where Conventional Meets Natural for a Healthier You

Parallel Health World News offers clarity and actionable knowledge for those eager to harmonize the best of both medical worlds, helping its audience achieve a truly integrative approach to health and wellness.

Advertise
Parallel Health World News
SeamanDan.com
Dan Seaman Media Press Pass

ABOUT US
SeamanDan LLC is a modern news media agency creating niche digital channels that inform and engage. We specialize in launching focused platforms that deliver impactful content.  Our current brands include:
Parallel Health World
AI Insights Hub
MLM News AI
Rider Safe News
Meme Crypto News
Rugged Trails Network
Recreation Wave
Outdoor Odyssey News
Eco-Innovation Hub
Metal Green Innovators
Autism Foundation News

At SeamanDan LLC, we don't just report the news we create platforms that build communities, foster trust, and drive forward-thinking conversations.  Can we build a channel for you?

© 2026 Parallel Health World News All Rights Reserved. 810 N Main St #187, Spearfish, SD 57783 . Contact Us . Terms of Service . Privacy Policy

{"company":"Parallel Health World News","address":", ,  ","city":"","state":"","zip":"","email":"seamandan@seamandan.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*